PRESS RELEASE
27 FEBRUARY 2012

VISCOGEL AB REPORTS POSITIVE RESULTS FROM SAFETY STUDIES

Viscogel AB today announced a successful completion of the toxicology studies that were carried out within the ViVac-project. The results showed that ViscoGel® was well tolerated even at higher doses and no unexpected effects were observed.

The recent toxicology studies were completed in order to prepare for the planned clinical trial with the company's vaccine adjuvant, ViscoGel®. The toxicology results were included in the recently submitted regulatory application to start a clinical phase I/II study in Sweden. The clinical trial will evaluate safety and efficacy of ViscoGel® in vaccination of healthy volunteers and is scheduled to start during 2012.

"The positive results from the toxicology studies is a regulatory prerequisite for initiating the first clinical trial" comments Peter Singer, CEO Viscogel AB. ""No adverse or unexpected effects were observed and ViscoGel® was well tolerated. This is a major milestone towards developing ViscoGel® into a safe and effective vaccine adjuvant."

Viscogel AB is together with 7 other European companies and academic institutions part of ViVac, a project funded by the European Union's Seventh Framework Programme. The overall aim of the project is to demonstrate clinical proof-of-concept for ViscoGel® in prophylactic vaccination. ViscoGel® is also being evaluated for use in allergy vaccines. More information on the ViVac project: www.vivac.se

Contact:
Peter Singer, CEO
Telefon: +46 (0)708 - 555 100
E-mail: peter.singer@viscogel.se
Website: www.viscogel.se

About Viscogel AB
Viscogel AB was founded in 2008 to further develop a novel high quality chitosan and viscoelastic gels for medical applications. The company has a unique expertise in chitosan and has developed Viscosan®, which is a medical grade chitosan of a quality previously not available in the market. The company has also patented a novel viscoelastic chitosan hydrogel - ViscoGel® - which can be mechanically processed to small particles. The particles have a large surface area available for interaction with the immune system, enable a rapid and improved immune response and can be injected. Viscogel AB is owned by the founders, management and private investors.

The research leading to these results has received funding from the European Union's Seventh Framework Programme managed by REA – Research Executive Agency http://ec.europa.eu/research/rea ([FP7/2007-2013] [FP7/2007-2011]) under grant agreement no 261954.